Category: Federal Cannabis

On December 28, 2025, two parallel developments highlighted the complex interplay between cannabis regulation, workplace safety, and medical science. The Department of Transportation confronted potential road safety challenges as marijuana moves toward Schedule III classification, while an Oregon Health & Science University-led systematic review provided new evidence about cannabis efficacy for chronic pain management. DOT’s […]

A historic shift in federal drug policy is underway. Following an executive order signed on December 18, 2025, the Trump administration has directed an expedited move to reclassify cannabis from Schedule I to Schedule III. This monumental decision is set to reshape the industry by dismantling long-standing financial barriers and introducing first-of-its-kind federal healthcare support for cannabinoid therapies.

President Donald Trump has publicly confirmed that his administration is “considering” an executive order to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act. Speaking to reporters on December 15, Trump stated, “We are looking at that very strongly,” according to Cannabis Business Times. This announcement follows last week’s reports of a […]

On December 12, 2025, the U.S. Supreme Court will meet behind closed doors to decide if it will hear Canna Provisions v. Bondi, a case that asks a simple but powerful question: can the federal government keep enforcing cannabis prohibition inside state legal markets? For cannabis operators, this is not an abstract constitutional debate. It sits […]